Daniel J. Rosenthal

Associate, Washington, DC

Biography

Overview

Daniel Rosenthal is an associate in the Firm's Global Antitrust/Competition Practice. He is widely considered a "go-to" practitioner for government merger and non-merger investigations, and counseling on antitrust issues, with a proven track record advising clients on complex cross-border transactions with multiple merger clearance requirements. 

Daniel brings creativity, deep knowledge, and a pragmatic approach when guiding clients in all phases of merger clearance before the Federal Trade Commission and Department of Justice. He has broad experience handling complex antitrust issues in a variety of industries, including healthcare, pharmaceuticals, biotechnology, manufacturing, petroleum, solid waste, transportation, automobile components, semiconductors, software, hardware, chemicals, energy, entertainment, and retail sales. 

Daniel has also successfully defended non-merger investigations, including investigations of violations of Section 8 of the Clayton Act, and has advocated for government intervention on behalf of parties adversely impacted by proposed mergers.

Clients rely on Daniel's advice on issues relating to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) as well as international merger notification requirements.

Clients also turn to Daniel on a variety of antitrust risk management issues relating to business initiatives such as joint ventures, pricing and distribution strategies, information and data-sharing, and trade association and industry-wide collaborative efforts.

In addition, Daniel helped develop White & Case's Global Antitrust Merger StatPak (WAMS), a first-of-its-kind resource providing information on merger control filing activity by competition authorities around the world. He has also authored and co-authored a number of articles and publications, including the US chapter of Merger Control, a comparative guide published by The Legal 500 (2018, 2019, 2020, 2021).

Bars and Courts
District of Columbia Bar
New York State Bar
Massachusetts State Bar
US District Court for the District of Columbia
Education
JD
University of Virginia School of Law
BA
Emory University
Languages
English

Experience

Recent representative transactions:

Tufin Software Technologies Ltd. on its acquisition by Turn/River Capital for a total of US$570 million.

Triton on its £1.2 billion acquisition of Clinigen Group plc.

Avast on its proposed US$9.2 billion merger with NortonLifeLock Inc. which is being structured as a takeover of Avast by NortonLifeLock.

DIC Corporation, a Japanese fine chemicals company, and its US subsidiary Sun Chemical Corporation, in connection with DIC's €1.15 billion acquisition of BASF's global pigments business, known as BASF Colors & Effects.

Kobalt Music Group on its US$430 million sale of certain subsidiaries to Sony Music Entertainment.

Continental Resources in its US$3.25 billion acquisition of certain entities and assets in the Permian Basin from affiliates of Pioneer Natural Resources Company, one of the largest independent oil and gas exploration and production companies in the United States.

Macquarie Infrastructure Partners in its US$2.9 billion acquisition of Cincinnati Bell 

Metso Corporation on the combination of Metso Minerals and Outotec Oyj under the name Metso Outotec.

Vertex Pharmaceuticals, Inc., in its acquisition of cystic fibrosis drug, CTP-656, from Concert Pharmaceuticals, Inc., for up to US$250 million.

Anthem, Inc., in its attempted US$54.2 billion acquisition of Cigna Corporation.

Shenzhen Hepalink Pharmaceuticals' acquisition of Scientific Protein Laboratories for US$337.5 million.  This transaction is one of the most significant Chinese investments in the US healthcare industry, and is the first major Chinese investment in the US in the Heparin industry following the 2008 Heparin-from-China contamination scare.

Calpine Corporation, in its US$17 billion sale to Energy Capital Partners, and a consortium of investors including Access Industries and Canadian Pension Plan Investment Board.

Iconix Brand Group, Inc. in the US$345 million sale of its entertainment division to DHX Media Ltd. Iconix's entertainment division included an 80 percent controlling interest in the Peanuts branded business, including content featuring Snoopy, Charlie Brown, Lucy and other well-known characters, and 100 percent of the Strawberry Shortcake business and its related characters.

Roark Capital Group and its portfolio company Arby's Restaurant Group, in Arby's US$2.9 billion acquisition of Buffalo Wild Wings, Inc.